Literature DB >> 9002325

Public health issues and clinical and neurological characteristics of the new variant of Creutzfeldt-Jakob disease and other human and animal transmissible spongiform encephalopathies: memorandum from two WHO meetings.

.   

Abstract

The transmissible spongiform encephalopathies (TSEs) include bovine spongiform encephalopathy (BSE), which was first described in 1986 in cattle in the United Kingdom, but has occurred subsequently also in other countries, and Creutzfeldt-Jakob disease (CJD) in humans, which is rare but with a worldwide distribution. Recently a new variant form of CJD, with a characteristic clinical and pathological phenotype, has been identified in the United Kingdom in a series of 11 young patients. This Memorandum reports the findings of two WHO Consultations. The first, held on 2-3 April 1996, issued conclusions and recommendations on certain animal products in order to protect the health of consumers. The second, held on 14-16 May 1996, examined, inter alia, the findings associated with the new variant of CJD, compared these findings with those for other TSEs, and proposed a protocol for the diagnosis and surveillance of CJD and related diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9002325      PMCID: PMC2486863     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  11 in total

1.  Infectious scrapie agent is apparently not as small as recent claims suggest.

Authors:  H Diringer; R H Kimberlin
Journal:  Biosci Rep       Date:  1983-06       Impact factor: 3.840

2.  STUDIES ON THE HEAT STABILITY AND CHROMATOGRAPHIC BEHAVIOUR OF THE SCRAPIE AGENT.

Authors:  G D HUNTER; G C MILLSON
Journal:  J Gen Microbiol       Date:  1964-11

3.  Proposal for a procedure for complete inactivation of the Creutzfeldt-Jakob disease agent.

Authors:  F Taguchi; Y Tamai; K Uchida; R Kitajima; H Kojima; T Kawaguchi; Y Ohtani; S Miura
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

4.  Purification of non-infectious ganglioside preparations from scrapie-infected brain tissue.

Authors:  A Di Martino; J Safar; M Ceroni; C J Gibbs
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  Newer data on the inactivation of scrapie virus or Creutzfeldt-Jakob disease virus in brain tissue.

Authors:  P Brown; R G Rohwer; D C Gajdusek
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

6.  Physical and chemical properties of the transmissible mink encephalopathy agent.

Authors:  R F Marsh; R P Hanson
Journal:  J Virol       Date:  1969-02       Impact factor: 5.103

7.  An experimental examination of the scrapie agent in cell membrane mixtures. 3. Studies of the operational size.

Authors:  R H Kimberlin; G C Millson; G D Hunter
Journal:  J Comp Pathol       Date:  1971-07       Impact factor: 1.311

8.  Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination.

Authors:  M Pocchiari; S Peano; A Conz; A Eshkol; F Maillard; P Brown; C J Gibbs; Y G Xi; E Tenham-Fisher; G Macchi
Journal:  Horm Res       Date:  1991

Review 9.  Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases)

Authors:  H Budka; A Aguzzi; P Brown; J M Brucher; O Bugiani; J Collinge; H Diringer; F Gullotta; M Haltia; J J Hauw
Journal:  Brain Pathol       Date:  1995-07       Impact factor: 6.508

10.  Can potential hazard of Creutzfeldt-Jakob disease infectivity be reduced in the production of human growth hormone? Inactivation experiments with the 263K strain of scrapie. Rapid communication.

Authors:  M Pocchiari; G Macchi; S Peano; A Conz
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.